HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health, Beauty And Wellness News: Warnings, Launches, Funds, Fines

This article was originally published in The Rose Sheet

Executive Summary

GMP, claim and branding problems in FDA's latest supplement sector warnings; FTC adding up Roca Labs' consumer redress; Thorne's hemp supplement sprouts again; SMPL earns passing grade from Zell Fund; Ocean Spray launches cranberry supplement; and ProMera reformulates full line.

You may also be interested in...



'Free Trial' Plus False Claims Equals More FTC Enforcement In Supplement Market

FTC on consecutive days announced court order closing a California business allegedly charging consumers for products and enrolling them in negative-option continuity plans without their consent after they responded to bogus free trial online offers, and started mailing 16,596 checks totaling more than $750,000 to consumers who bought deceptively marketed supplements from a Maine firm that also lured customers with a free trial pitch.

Thorne Research Rebranding Launches With At-Home Biomarker Tests

Thorne Research rebrands, launches at-home biomarker, adds exclusive provider and technology agreements and gains Mitsui Group funding.

Industry Roundup: Children’s Motrin Trial Verdict, Gag’s Up For Roca Labs

Jury finds J&J/McNeil not liable to warn on Children’s Motrin labels about a risk of severe skin conditions; gag’s up for Roca Labs; Omega Protein could be available; and more news in brief.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel